BED BATH & BEYOND INC. AND SUBSIDIARIES

Consolidated Balance Sheets (in thousands, except per share data)

	February 27, 2016			February 28, 2015	
Assets					
Current assets:					
Cash and cash equivalents	\$	515,573	\$	875,574	
Short term investment securities		86,197		109,992	
Merchandise inventories		2,848,119		2,731,881	
Other current assets		376,073		366,156	
Total current assets		3,825,962		4,083,603	
Long term investment securities		71,289		97,160	
Property and equipment, net		1,725,043		1,676,700	
Goodwill		487,169		486,279	
Other assets		389,477		415,251	
Total assets	\$	6,498,940	\$	6,758,993	
Liabilities and Shareholders' Equity					
Current liabilities:					
Accounts payable	\$	1,100,958	\$	1,156,368	
Accrued expenses and other current liabilities		409,445		403,547	
Merchandise credit and gift card liabilities		297,930		306,160	
Current income taxes payable		58,892		76,606	
Total current liabilities		1,867,225		1,942,681	
Deferred rent and other liabilities		499,368		493,137	
Income taxes payable		72,807		79,985	
Long term debt		1,500,000		1,500,000	
Long term debt		1,300,000	_	1,300,000	
Total liabilities		3,939,400		4,015,803	
Commitments and contingencies					
Shareholders' equity:					
Preferred stock - \$0.01 par value; authorized - 1,000 shares; no shares issued or outstanding		_		-	
Common stock - \$0.01 par value; authorized - 900,000 shares; issued 337,613 and 336,667 shares,					
respectively; outstanding 156,690 and 174,178 shares, respectively		3,377		3,367	
Additional paid-in capital		1,884,813		1,796,692	
Retained earnings		10,394,865		9,553,376	
Treasury stock, at cost		(9,668,517)		(8,567,932)	
Accumulated other comprehensive loss		(54,998)		(42,313)	
Total shareholders' equity		2,559,540		2,743,190	

 $See\ accompanying\ Notes\ to\ Consolidated\ Financial\ Statements.$

Consolidated Statements of Earnings Bed Bath & Beyond Inc. and Subsidiaries

(in thousands, except per share data)			ED			
		February 27, 2016		February 28, 2015		March 1, 2014
Net sales	\$	12,103,887	\$	11,881,176	\$	11,503,963
Cost of sales		7,483,577		7,261,397		6,938,381
000 010000		7,403,377		7,201,377		0,230,301
Gross profit		4,620,310		4,619,779		4,565,582
Selling, general and administrative expenses		3,205,407		3,065,486		2,950,995
Operating profit		1,414,903		1,554,293		1,614,587
operating profit		1,414,703		1,554,275		1,014,507
Interest expense, net		87,458		50,458		1,140
Earnings before provision for income taxes		1,327,445		1,503,835		1,613,447
Provision for income taxes		485,956		546,361		591,157
Net earnings	\$	841,489	\$	957,474	\$	1,022,290
1 (or cumings	Ψ	041,407	Ψ	751,414	Ψ	1,022,270
Net earnings per share - Basic	\$	5.15	\$	5.13	\$	4.85
Net earnings per share - Diluted	\$	5.10	\$	5.07	\$	4.79
Weighted average shares outstanding - Basic		163,257		186,659		210,710
Weighted average shares outstanding - Diluted		165,016		188,880		213,363

 $See\ accompanying\ Notes\ to\ Consolidated\ Financial\ Statements.$

Consolidated Statements of Comprehensive Income *Bed Bath & Beyond Inc. and Subsidiaries*

]	CAL YEAR ENDED	ED		
(in thousands)		February 27, 2016		February 28, 2015	March 1, 2014	
Net earnings	\$	841,489	\$	957,474 \$	1,022,290	
Other comprehensive (loss) income:						
Change in temporary valuation adjustment of auction rate securities, net of taxes Pension adjustment, net of taxes Currency translation adjustment	_	1,584 (351) (13,918)		143 (5,552) (23,057)	(792) 3,249 (11,984)	
Other comprehensive loss	_	(12,685)		(28,466)	(9,527)	
Comprehensive income	\$	828,804	\$	929,008 \$	1,012,763	

See accompanying Notes to Consolidated Financial Statements.

Consolidated Statements of Cash Flows Bed Bath & Beyond Inc. and Subsidiaries

	FISCAL YEAR ENDED					
(in thousands)	February 27, 2016	February 28, 2015	March 1, 2014			
Carl Elawa form Occasion Astinition						
Cash Flows from Operating Activities: Net earnings	\$ 841,489	\$ 957.474 \$	1 022 200			
	\$ 841,489	\$ 957,474 \$	1,022,290			
Adjustments to reconcile net earnings to net cash provided by operating activities:	272.047	220 102	220.116			
Depreciation and amortization	273,947	239,193	220,116			
Stock-based compensation	66,965	66,539	56,244			
Excess tax benefit from stock-based compensation	(10,370)	(14,561)	(19,126)			
Deferred income taxes	56,997	(22,295)	11,729			
Other	398	(2,244)	(1,784)			
(Increase) decrease in assets:			(, , = = = =)			
Merchandise inventories	(121,748)	(161,506)	(117,926)			
Trading investment securities	(2,270)	(9,530)	(11,382)			
Other current assets	(16,171)	19,012	(5,287)			
Other assets	(27,904)	(254)	(3,812)			
(Decrease) increase in liabilities:						
Accounts payable	(48,148)	44,563	179,522			
Accrued expenses and other current liabilities	6,694	18,494	(1,336)			
Merchandise credit and gift card liabilities	(7,872)	22,520	33,014			
Income taxes payable	(15,036)	17,656	15,729			
Deferred rent and other liabilities	15,213	3,428	3,735			
Net cash provided by operating activities	1,012,184	1,178,489	1,381,726			
Cash Flows from Investing Activities:						
Purchase of held-to-maturity investment securities	(103,017)	(298,094)	(1,156,634)			
Redemption of held-to-maturity investment securities	126,875	677,500	1,117,500			
Redemption of available-for-sale investment securities	28,905	-	-			
Capital expenditures	(328,395)	(330,637)	(320,812)			
Investment in unconsolidated joint venture	(320,335)	(550,057)	(3,436)			
Net cash (used in) provided by investing activities	(275,632)	48,769	(363,382)			
rect easii (used iii) piovided by investing activities	(273,032)	46,709	(303,382)			
Cash Flows from Financing Activities:						
Proceeds from exercise of stock options	9,109	41,197	54,815			
Proceeds from issuance of senior unsecured notes	· -	1,500,000	_			
Payment of deferred financing costs	_	(10,092)	-			
Payment of other liabilities	(7,646)	-	-			
Excess tax benefit from stock-based compensation	10,370	14,561	19,126			
Repurchase of common stock, including fees	(1,100,585)	(2,250,597)	(1,283,995)			
Net cash used in financing activities	(1,088,752)	(704,931)	(1,210,054)			
Effect of exchange rate changes on cash and cash equivalents	(7,801)	(13,269)	(6,745)			
Not (decrease) in success in each and each souriselents	(260,001)	500.058	(100 455)			
Net (decrease) increase in cash and cash equivalents	(360,001)	509,058	(198,455)			
Cash and cash equivalents:						
Beginning of period	875,574	366,516	564,971			
End of period	\$ 515,573	\$ 875,574 \$	366,516			

See accompanying Notes to Consolidated Financial Statements.